KL-50 in post TMZ MMR-deficient GBM
02/22/25 • 21 min
Dr. Iyad Alnahhas interviews Dr. Craig Horbinski about his and his team's recent manuscript entitled "The novel DNA cross-linking agent KL-50 is active against patient-derived models of new and recurrent post-temozolomide mismatch repair-deficient glioblastoma", published online in Neuro-Oncology in December 2024.
Dr. Iyad Alnahhas interviews Dr. Craig Horbinski about his and his team's recent manuscript entitled "The novel DNA cross-linking agent KL-50 is active against patient-derived models of new and recurrent post-temozolomide mismatch repair-deficient glioblastoma", published online in Neuro-Oncology in December 2024.
Previous Episode
Measurable disease per FET-PET vs MRI in GBM
Dr. Iyad Alnahhas interviews Dr. Nathalie Albert about her and her team's recent manuscript entitled: "Measurable disease as baseline criterion for response in glioblastoma: A comparison of PET-based (PET RANO 1.0) and MRI-based (RANO) assessments", published online in Neuro-Oncology in January 2025.
Next Episode
Vorasidenib in IDH mutant glioma
Description: Dr. Ankush Bhatia interviews Drs. Macarena de la Fuente and Mehdi Touat about their recent manuscript entitled: "The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma" published online in Neuro-Oncology in December 2024. Link: https://doi.org/10.1093/neuonc/noae259
If you like this episode you’ll love
Episode Comments
Generate a badge
Get a badge for your website that links back to this episode
<a href="https://goodpods.com/podcasts/neuro-oncology-the-podcast-338034/kl-50-in-post-tmz-mmr-deficient-gbm-86030689"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to kl-50 in post tmz mmr-deficient gbm on goodpods" style="width: 225px" /> </a>
Copy